Inovio Pharmaceuticals (INO) stock Forecast for 2022 – 2026
Last update: 05-24-2022, 4:44
Sector: HealthcareThe share price of Inovio Pharmaceuticals, Inc. (INO) now
What analysts predict:: $5.67
52-week high/low: $10.33 / $1.6
50/200 Day Moving Average: $3.117 / $5.51
This figure corresponds to the average price over the previous 50/200 days. For Inovio Pharmaceuticals stocks, the 50-day moving average is the resistance level today.
For Inovio Pharmaceuticals stocks, the 200-day moving average is the resistance level today.
Are you interested in Inovio Pharmaceuticals, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Inovio Pharmaceuticals stock price in 2022, 2023, 2024, 2025, 2026. How much will one Inovio Pharmaceuticals share be worth in 2022 - 2026?
When should I take profit in Inovio Pharmaceuticals stock? When should I record a loss on Inovio Pharmaceuticals stock? What are analysts' forecasts for Inovio Pharmaceuticals stock? What is the future of Inovio Pharmaceuticals stock?
We forecast Inovio Pharmaceuticals stock performance using neural networks based on historical data on Inovio Pharmaceuticals stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Inovio Pharmaceuticals stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2022, 2023, 2024, 2025 and 2026)
The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Inovio Pharmaceuticals shares. This happens once a day.
Historical and forecast chart of Inovio Pharmaceuticals stock
The chart below shows the historical price of Inovio Pharmaceuticals stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Inovio Pharmaceuticals stock price can be found in the table below.
Long-term forecasts by years.
Inovio Pharmaceuticals daily forecast for a month
| Date | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| May 26 | 1.89 | 1.87 | 1.96 | 4.97 |
| May 27 | 1.94 | 1.86 | 2.01 | 7.64 |
| May 28 | 1.93 | 1.86 | 1.97 | 6.41 |
| May 29 | 1.88 | 1.82 | 1.95 | 7.26 |
| May 30 | 1.96 | 1.91 | 2.00 | 4.82 |
| May 31 | 1.92 | 1.86 | 1.99 | 6.90 |
| Jun 01 | 1.96 | 1.92 | 1.99 | 3.15 |
| Jun 02 | 1.93 | 1.86 | 1.99 | 7.16 |
| Jun 03 | 2.00 | 1.94 | 2.07 | 6.69 |
| Jun 04 | 1.95 | 1.92 | 2.02 | 5.23 |
| Jun 05 | 1.95 | 1.88 | 2.00 | 6.06 |
| Jun 06 | 2.02 | 1.97 | 2.05 | 3.94 |
| Jun 07 | 2.07 | 1.99 | 2.15 | 7.73 |
| Jun 08 | 2.04 | 1.98 | 2.10 | 5.92 |
| Jun 09 | 2.03 | 1.95 | 2.10 | 7.47 |
| Jun 10 | 2.04 | 1.97 | 2.06 | 4.49 |
| Jun 11 | 2.08 | 2.01 | 2.11 | 5.28 |
| Jun 12 | 2.03 | 1.95 | 2.05 | 4.98 |
| Jun 13 | 1.98 | 1.93 | 2.01 | 4.37 |
| Jun 14 | 1.98 | 1.93 | 2.03 | 5.28 |
| Jun 15 | 1.98 | 1.91 | 2.00 | 4.87 |
| Jun 16 | 1.94 | 1.91 | 1.99 | 3.86 |
| Jun 17 | 1.96 | 1.93 | 1.98 | 2.17 |
| Jun 18 | 1.93 | 1.87 | 1.99 | 6.68 |
| Jun 19 | 1.89 | 1.87 | 1.94 | 4.16 |
| Jun 20 | 1.89 | 1.82 | 1.94 | 6.43 |
| Jun 21 | 1.89 | 1.82 | 1.91 | 4.66 |
| Jun 22 | 1.92 | 1.89 | 1.95 | 3.04 |
| Jun 23 | 1.89 | 1.81 | 1.93 | 6.66 |
| Jun 24 | 1.86 | 1.82 | 1.93 | 5.88 |
Inovio Pharmaceuticals Daily Price Targets
Inovio Pharmaceuticals Stock Forecast 05-26-2022.
Pessimistic target level: 1.87
Optimistic target level: 1.96
Inovio Pharmaceuticals Stock Forecast 05-27-2022.
Pessimistic target level: 1.86
Optimistic target level: 2.01
Inovio Pharmaceuticals Stock Forecast 05-28-2022.
Pessimistic target level: 1.86
Optimistic target level: 1.97
Inovio Pharmaceuticals Stock Forecast 05-29-2022.
Pessimistic target level: 1.82
Optimistic target level: 1.95
Inovio Pharmaceuticals Stock Forecast 05-30-2022.
Pessimistic target level: 1.91
Optimistic target level: 2.00
Inovio Pharmaceuticals Stock Forecast 05-31-2022.
Pessimistic target level: 1.86
Optimistic target level: 1.99
INO (INO) Monthly Stock Prediction for 2022
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jun. | 1.86 | 1.79 | 1.95 | 7.93 |
| Jul. | 1.78 | 1.67 | 1.86 | 10.50 |
| Aug. | 1.80 | 1.73 | 1.92 | 9.92 |
| Sep. | 1.87 | 1.83 | 1.94 | 5.96 |
| Oct. | 1.80 | 1.74 | 1.88 | 7.18 |
| Nov. | 1.73 | 1.60 | 1.77 | 9.67 |
| Dec. | 1.71 | 1.67 | 1.77 | 5.80 |
Inovio Pharmaceuticals forecast for this year
Inovio Pharmaceuticals Stock Prediction for Jun 2022
An downtrend is forecast for this month with an optimal target price of $1.8584. Pessimistic: $1.79. Optimistic: $1.95
Inovio Pharmaceuticals Stock Prediction for Jul 2022
An downtrend is forecast for this month with an optimal target price of $1.77663. Pessimistic: $1.67. Optimistic: $1.86
Inovio Pharmaceuticals Stock Prediction for Aug 2022
An uptrend is forecast for this month with an optimal target price of $1.79973. Pessimistic: $1.73. Optimistic: $1.92
Inovio Pharmaceuticals Stock Prediction for Sep 2022
An uptrend is forecast for this month with an optimal target price of $1.86812. Pessimistic: $1.83. Optimistic: $1.94
Inovio Pharmaceuticals Stock Prediction for Oct 2022
An downtrend is forecast for this month with an optimal target price of $1.79526. Pessimistic: $1.74. Optimistic: $1.88
Inovio Pharmaceuticals Stock Prediction for Nov 2022
An downtrend is forecast for this month with an optimal target price of $1.72524. Pessimistic: $1.60. Optimistic: $1.77
Inovio Pharmaceuticals Stock Prediction for Dec 2022
An downtrend is forecast for this month with an optimal target price of $1.71317. Pessimistic: $1.67. Optimistic: $1.77
Inovio Pharmaceuticals (INO) Monthly Stock Prediction for 2023
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 1.67 | 1.60 | 1.78 | 10.22 |
| Feb | 1.59 | 1.51 | 1.62 | 6.96 |
| Mar | 1.61 | 1.53 | 1.69 | 9.25 |
| Apr | 1.50 | 1.45 | 1.59 | 8.70 |
| May | 1.52 | 1.43 | 1.60 | 10.31 |
| Jun | 1.59 | 1.51 | 1.70 | 11.06 |
| Jul | 1.66 | 1.61 | 1.70 | 5.25 |
| Aug | 1.57 | 1.45 | 1.70 | 14.66 |
| Sep | 1.72 | 1.66 | 1.78 | 6.38 |
| Oct | 1.78 | 1.72 | 1.87 | 7.90 |
| Nov | 1.74 | 1.68 | 1.84 | 8.44 |
| Dec | 1.80 | 1.72 | 1.88 | 8.55 |
Inovio Pharmaceuticals (INO) Monthly Stock Prediction for 2024
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 1.66 | 1.54 | 1.78 | 13.31 |
| Feb | 1.67 | 1.54 | 1.78 | 13.56 |
| Mar | 1.68 | 1.63 | 1.80 | 9.26 |
| Apr | 1.72 | 1.63 | 1.82 | 10.48 |
| May | 1.72 | 1.63 | 1.76 | 7.24 |
| Jun | 1.63 | 1.53 | 1.69 | 9.76 |
| Jul | 1.58 | 1.51 | 1.64 | 8.35 |
| Aug | 1.54 | 1.48 | 1.63 | 9.36 |
| Sep | 1.47 | 1.39 | 1.58 | 11.87 |
| Oct | 1.50 | 1.45 | 1.56 | 6.72 |
| Nov | 1.49 | 1.41 | 1.57 | 10.31 |
| Dec | 1.40 | 1.36 | 1.48 | 8.52 |
Inovio Pharmaceuticals (INO) Monthly Stock Prediction for 2025
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 1.36 | 1.25 | 1.46 | 14.21 |
| Feb | 1.36 | 1.31 | 1.39 | 5.96 |
| Mar | 1.42 | 1.34 | 1.49 | 10.03 |
| Apr | 1.39 | 1.33 | 1.44 | 7.74 |
| May | 1.40 | 1.33 | 1.49 | 10.99 |
| Jun | 1.54 | 1.44 | 1.61 | 10.69 |
| Jul | 1.69 | 1.63 | 1.80 | 9.35 |
| Aug | 1.85 | 1.71 | 1.93 | 11.16 |
| Sep | 1.90 | 1.80 | 1.96 | 8.13 |
| Oct | 1.97 | 1.84 | 2.08 | 11.65 |
| Nov | 2.04 | 1.90 | 2.13 | 10.92 |
| Dec | 1.99 | 1.92 | 2.04 | 5.78 |
Inovio Pharmaceuticals (INO) Monthly Stock Prediction for 2026
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 2.04 | 1.92 | 2.15 | 10.61 |
| Feb | 2.02 | 1.96 | 2.08 | 6.10 |
| Mar | 2.11 | 1.95 | 2.20 | 11.13 |
| Apr | 2.06 | 1.92 | 2.19 | 12.52 |
| May | 2.13 | 1.96 | 2.28 | 13.84 |
| Jun | 2.29 | 2.14 | 2.37 | 9.83 |
| Jul | 2.30 | 2.19 | 2.47 | 11.28 |
| Aug | 2.36 | 2.27 | 2.48 | 8.20 |
| Sep | 2.41 | 2.33 | 2.48 | 6.12 |
| Oct | 2.33 | 2.15 | 2.46 | 12.61 |
| Nov | 2.42 | 2.31 | 2.61 | 11.57 |
| Dec | 2.53 | 2.42 | 2.72 | 11.26 |
Inovio Pharmaceuticals information and performance
Inovio Pharmaceuticals, Inc. a biotechnology company specializing in the discovery, development and commercialization of DNA drugs to treat, cure and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. Its SynCon immunotherapy design has the ability to disrupt the immune system’s tolerance to cancer cells and facilitate the cross-protection of strains against unrivaled and matched pathogens. The company participates in the conduct and planning of clinical trials of its DNA drugs for the treatment of HPV-associated cancers, including dysplasia of the cervix, vulva and anus; HPV-associated cancers, including cancers of the head and neck, cervix, anal canal, penis, vulva, and vagina; other HPV-associated diseases such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East respiratory syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and employees are ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., Bill & Melinda Gates Foundation, Epidemic Preparedness Innovation Coalition (EPIR), Defense Advanced Research Projects Agency (DARPA), Life Sciences GeneOne. HIV Vaccine Threat Reduction Forensic Network, Defense Consortium Medical Weapons Agency (GCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergic and Infectious Diseases, Life Science Plumb Line, Regeneron Pharmaceuticals, Roche / Genentech, University Pennsylvania, University. Walter Reed Army Research Institute and Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support the INO-4800 DNA research vaccine currently in Phase I of the COVID-19 clinical trials; and partnerships with the International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Inovio Pharmaceuticals Address
6769 MESA RIDGE RD., SAN DIEGO, CA, US
Market Capitalization: 455 792 000 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: -108 041 976 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: None
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: N/A
Price/earnings to growth
DPS: N/A
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
DY: N/A
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS: -1.454
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: -0.85
Trailing PE: -
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: -
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: 54.6
Enterprise Value (EV) /Revenue
EV To EBITDA: -
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 229041000
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A